Dr. Danielle Lane

Dr. Danielle Lane |Clyto Access

Lane Fertility Institute San Francisco, USA

Speaker

Expertise: Medical Director

Biography:

Danielle E. Lane, M.D. is the founder and Medical Director of the Lane Fertility Institute. She holds a Bachelor’s Degree of Science in Physiology from McGill University. She completed her medical training at the University of Pittsburgh and her residency in Obstetrics and Gynecology at Yale-New Haven Hospital, Yale University. She then completed her fellowship in Reproductive Endocrinology and Infertility at the prestigious University of California, San Francisco.

After training at one of the most successful IVF programs in the United States, Dr. Lane began to establish practices that combined the best success rates with a model for individualized and compassionate fertility care. In 2002, she developed the Center for Reproductive Health at Kaiser Permanente (Napa-Solano Service area). After successfully establishing this practice, Dr. Lane replicated her model for outstanding fertility success and individualized patient care and opened her first private practice office in Marin County. Following its success, she opened an office in San Francisco.

Dr. Lane is committed to giving back to the field of fertility and to the community. Her two missions are (1) educating women about the importance of fertility preservation and having a plan for building their family; and (2) developing a low-cost model for in vitro fertilization that meets the needs of a larger population of women.

,

Presentation:

Title: Improving Reproductive Outcomes using IVF and PGT

Abstract:

Pre-implantation genetic testing (PGT) is a form of prenatal testing that is performed on early generally blastocyst embryos. This testing is unique in that it is performed prior to the transfer of the embryo into the uterus. PGT is not a therapeutic procedure for the embryos. Instead, it is a diagnostic test only, and therefore does not change DNA or any other genetic-related structures in the embryo. PGT is able to identify whether an embryo carries a single gene disorder, or a number of chromosomes, which could lead to a failed implantation, a miscarriage or a child with a physical or developmental defect. Information from PGT can be used by the couple and their providers to select which embryos to transfer with a high likelihood of a resulting normal pregnancy. Physicians and patients should be aware that there is much that remains unknown about the long-term effects of embryo biopsy on any developing fetus. Although PGT is thought to be without serious side effects, PGT should only be considered after patients are thoroughly counseled to weigh the risks of what is unknown about the technology and the biopsy itself against the expected benefit of its use.

,

Related Conferences :